Riskpilot← Back to searchSign inGet full accessADD-X Biotech AB
ABActiveOrg 5562895820Nytäppevägen 3Energy recovery · NACE 3822Est. 19860 employees
Revenue 2024
SEK 0
EBITDA margin
—
+100% vs 2023
Equity ratio
85.2%
Financial strength
Net profit 2024
SEK -238
+100% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -250 | +100% |
| Net profit | SEK -238 | +100% |
| Total assets | SEK 3,1M | +0% |
| Equity | SEK 2,6M | +0% |
| Employees | 0 | — |
Legal name
ADD-X Biotech AB
Org number
5562895820
Legal form
Aktiebolag
NACE code
3822 · Energy recovery
Founded
10 december 1986
Share capital
SEK 400 727
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall sälja material och know-how inom området komposter- och biologiskt nedbrytbara produkter och därmed förenlig verksamhet.
Address
Nytäppevägen 3
Email
markus.jorgensen@leathermaster.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 926 | 1 129 | 19 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 16 | −559 | −62 | −65 | −0 |
| Depreciation & amort. | −0 | −1 300 | −0 | — | — |
| EBIT | 16 | −1 859 | −62 | −65 | −0 |
| Net financials | −151 | −58 | 62 | −2 | 0 |
| Profit before tax | −135 | −1 917 | −1 | — | — |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −135 | −1 917 | −1 | −67 | −0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 128 | 3 612 | 3 173 | 3 106 | 3 106 |
| Equity | 4 204 | 2 287 | 2 714 | 2 647 | 2 646 |
| Long-term debt | 0 | 0 | 0 | 444 | 444 |
| Short-term debt | 1 925 | 1 325 | 459 | 15 | 15 |
| Total debt | 1 925 | 1 325 | 459 | 459 | 459 |
EBITDA margin
-25000.0%
This company
15.8%
Market median
-158328% vs market
20202024
Equity ratio
85.2%
This company
38.2%
Market median
+123% vs market
20202024
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
-23800.0%
This company
8.1%
Market median
-293927% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
PM Audit | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
K.M.L Invest Aktiebolag
ADD-X Biotech AB Board members of ADD-X Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Martin Bengtsson | Audit | 0 companies |
| Klas Johan Markus Jörgensen | Chief Executive Officer | 0 companies |
| Åsa Kristina Jörgensen | Deputy Board Member | 0 companies |
| Sophia Kristina Jakobsson | Chairman | 0 companies |